The Trump administration has postponed its planned 100 percent tariffs on pharmaceutical imports, offering drugmakers additional time to expand U.S. manufacturing operations. The policy, announced last week, would target all branded and patented drugs produced abroad unless companies establish production facilities in America.
According to officials, enforcement is still being structured under Section 232 of the Trade Expansion Act, which allows tariffs on goods deemed critical to national security. Pfizer confirmed it has secured a three-year grace period, though the White House maintains the tariffs are still under consideration.
The move signals a balancing act between pressuring pharmaceutical giants to reshore production and ensuring continued drug availability. Industry leaders have warned that sweeping tariffs could disrupt supply chains and drive up costs, while the administration frames the policy as essential to reducing foreign dependence. For now, the fate of the tariff plan remains uncertain.
